We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Newly Developed Point-of-Care Hemoglobinometer Evaluated

By LabMedica International staff writers
Posted on 10 Dec 2014
Print article
Image: The TrueHb hemometer testing kit (Photo courtesy of the Indian Institute of Technology Delhi).
Image: The TrueHb hemometer testing kit (Photo courtesy of the Indian Institute of Technology Delhi).
Hemoglobin (Hb) concentration is routinely measured using automated analyzers, and although these counters are very accurate and reliable, they are expensive and too cumbersome for portability.

Portable hemoglobinometer can potentially provide the solution to the challenges as they are affordable, precise, and convenient and require only a tiny sample of capillary or venous blood, do not require any calibration and display digital results immediately.

Scientists at the Indian Institute of Technology Delhi (IITD; New Delhi, India) collected 200 hundred randomly selected venous blood samples, submitted for hemogram study at the Department of Hematology, All India Institute of Medical Sciences (New Delhi, India). The hemoglobin values of these samples were evenly spread. There were 67, 76, and 57 samples in the ranges of 3.4–8 g/dL, 8–12.5 g/dL, and 12.5–20 g/dL respectively.

The investigators evaluated the performance of the portable hemometer called TrueHb (New Delhi, India) developed by IITD, and compared it with an automated five-part hematology analyzer intended for in vitro diagnostic use in clinical laboratories, the Sysmex counter XT 1800i (Sysmex; Kobe, Japan). The two set of values were comparatively analyzed and the repeatability of the performance of TrueHb was also evaluated against Sysmex value.

The scatter plot of TrueHb values and Sysmex values showed linear distribution with positive correlations. The intraclass correlation (ICC) values between the two set of values was found to be very high. The mean difference in Bland–Altman plots of TrueHb values against the Sysmex values was found to be −0.02, with limits of agreement between -0.777 and 0.732 g/dL. Statistical analysis suggested good repeatability in results of TrueHb, having a low mean coefficient of variation (CV) of 2.22, against 4.44, that of Sysmex values, and 95% confidence interval of 1.99 to 2.44, against 3.85 to 5.03, that of Sysmex values.

The authors concluded that a strong positive correlation between the two measurements devices suggest that the newly developed hemometer, TrueHb, can potentially replace a pathology laboratory analyzer for the purpose of measuring hemoglobin in blood samples. Keeping the performance of TrueHb in view, the newly developed device exhibited the potential to become a dependable tool for healthcare providers for measuring and monitoring hemoglobin levels of patients in conventional healthcare setups as well as in field studies. The study was published on November 22, 2014, in the International Journal of Laboratory Hematology.

Related Links:
Indian Institute of Technology Delhi 
All India Institute of Medical Sciences
TrueHb



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.